Global Business Innovation Programme: Health & Medical Technologies - Singapore

To apply for this GBIP, you must be:

• a UK-based innovation-led company with ambitions to grow and scale globally
• a company with fewer than 250 employees
• the CEO, founder, or senior decision maker in the business
• able to attend all workshops and complete all activities

Businesses that have been on a previous GBIP (in the same market and/or technology area) will need to demonstrate they have exploited the previous opportunity to be considered and how this programme will add significant additional benefit.  Preference may be given to businesses that have not participated previously.

Innovate UK is committed to improving the diversity of who we support. We welcome applications from under-represented groups.

Successful applicants will benefit from an intensive 9-12 month, three phase programme with bespoke support from an innovation and growth specialist throughout.

Get ready: A two-day preparation workshop to build knowledge and understanding of the market and opportunities, including cultural aspects, how to do business, protecting Intellectual Property, and support to better articulate your value proposition.

Visit the market: Explore the innovation opportunities first-hand through pre-arranged matchmaking events, meetings with key contacts, research organisations and potential collaborators and partners.

Exploit the opportunity: An exploitation workshop and one-to-one bespoke support from an innovation and growth specialist to help you follow-up and maximise the opportunities identified through the programme.

Singapore’s Research, Innovation and Enterprise 2025 Plan aims to better transform and protect health, advance human potential & create economic value for Singapore. Priorities include transforming and protecting health through (i) shifting the focus towards both health promotion & disease prevention as the population ages (ii) supporting the health system to become more data-driven and patient-centric to deliver value-based care through the innovative use of both technology and digital solutions at scale (iii) using data analytics to support public health actions & telemedicine to deliver quality care to the wider population and (iv) expanding the national precision medicine research programme. A further priority is maximising economic value by growing a vibrant mix of start-ups and scale-ups with a strong translational ecosystem, with a particular focus on biotech companies.

With the Asia-Pacific Medical Technology (MedTech) market expected to grow to US$225 billion by 2030, Singapore is strategically placed to enable companies to tap into these regional opportunities, and Singapore’s network of top universities, research institutions and innovative start-ups also enable MedTech companies to fully engage with a vibrant open innovation ecosystem.

Singapore has an advanced digital economy and is consistently ranked as one of the world’s most innovative cities. Innovate UK has a thriving bilateral partnership with Enterprise Singapore. Since 2021, there have been 2 three-yearMoUs agreed (latest 2024-27), setting out joint activities to be undertaken to support stronger UK-Singapore co-innovation. In the agreements, Health & Medical Technologies have been identified as a specific area of collaboration. In addition, through open annual bilateral CR&D funding calls (in operation since 2022), health and medical technology proposals have been one of the largest sources of responses between the UK and Singapore, demonstrating significant industry demand for collaboration in this field.

• Introductory briefing with the British High Commission
• Visits to research and technology organisations
• Company visits and meetings with key contacts
• Focused B2B events, receptions and 1-2-1 meetings
• High quality networking opportunities

Applications will be considered from a wide range of innovative Medical & Health Technologies companies that focus on, but not limited to:

• Medical devices such as diagnostic equipment, surgical instruments, orthopaedic devices, dental devices, ophthalmic devices, wound care products.
• In-vitro diagnostics such as blood testing kits, point-of-care testing, molecular diagnostics.
• Therapeutic devices such as infusion pumps, dialysis machines, respiratory devices, insulin pumps, cardiovascular devices.
• Implants and biocompatible devices such as cardiac implants, neurostimulation devices, cochlear implants, orthopaedic implants, dental implants.
• Health monitoring and wearable devices such as wearable health trackers, remote patient monitoring, telemedicine devices, software solutions for clinical decision support and health information exchange.
• Robotic and AI-assisted devices such as robotic surgery systems, AI diagnostic tools.

Areas of focus that are not being considered for this GBIP are:

• Therapeutics and medicines such as cell and gene therapies, antibiotics, vaccines, biologics and tissue engineering.
• Sterilisation and infection control products such as but not limited to autoclaves, disinfectants and sanitizers and personal protective equipment.

• Build market knowledge and intelligence
• Seed new business partnerships, develop RD&I collaborations, and identify partners for bilateral funding calls
• Introductions to senior figures and influential contacts
• Raise your profile and stimulate new business opportunities and ideas
• Improve your value proposition, hone your skills, and grow in confidence to tackle global markets
• Connect with peers, expand your network, and learn from like-minded, ambitious businesses

• Applicant briefing – Wednesday 9^th July, 10-11am
• Application deadline – Sunday 24^th August
• Application outcome – Friday 5^th September
• Get ready workshop – Tuesday 16^th & Wednesday 17^th September
• Market Visit – Saturday 15^th to Friday 21^st November
• Exploit the opportunity workshop – Wednesday 11^th February 2026

Innovate UK will fund and organise flights, accommodation, in-market travel, and conference fees for successful applicants.

Innovate UK will also pay for any reasonable adjustments throughout the initiative.  Only one representative from each company will be funded and the same person is required to participate in all parts of the programme.

On acceptance to the programme a commitment fee of £1000 will be obtained from each delegate, which will be refunded on completion of the full activities and agreed work plan.

Non-completion after formal acceptance may result in forfeiting some or all of the commitment fee.